Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global 3D bioprinting market was valued at US$ 1.65 billion in 2021 and is expected to register a revenue CAGR of 15.6% to reach US$ 6.08 billion by 2030.

3D Bioprinting Market Fundamentals 

3D bioprinting is a type of additive manufacturing that uses cells and biomaterials to generate 3-dimensional (3D) constructions that operate as tissues. These biomaterials are further referred to as bio-inks, which are used to replicate biological tissues. Bioprinting has shown massive potential in the past decade and has a wide range of applications in various areas, such as regenerative medicine, drug discovery and development, and 3D cell culture.

3D bioprinting is frequently used in the development of regenerative technologies and personalized medications, as it produces highly tailored tissue models that outperform traditional tissue engineering approaches. The model can replicate actual tissue and be created in a high-throughput way using microarrays. These 3D tissue models can help in analyzing the efficacy of potential treatments, improving their uptake.

[2574524]

3D Bioprinting Market Dynamics

The global 3D bioprinting market has illustrated significant revenue growth in the past few years and is expecting a continued trend. The revenue growth of this market can be attributed to various factors, such as growing need for organ transplantation & care and large unmet needs in regenerative medicine and drug discovery and development. Growing influence of 3D bioprinting, with its key role in healthcare facilities, especially in drug testing and tissue engineering, further adds to market revenue growth. 

Rapidly growing R&D activities in 3D tissue modeling and advancements in technologies and materials encourage overall market revenue growth. Furthermore, increasing private and public investment/funding for R&D initiatives supports revenue growth in the market.

Conversely, lack of specialized professionals and high costs of 3D bioprinting processes are likely to restrain revenue growth in the market during the forecast period. 

3D Bioprinting Market Ecosystem

The global 3D bioprinting market is analyzed based on five parameters: components, materials, application, end user, and region. 

3D Bioprinting Market by Components

[2455646]

Based on the components, the global 3D bioprinting market is segmented into 3D bioprinters and bio-inks.

The 3D bioprinters segment dominates the market with the largest revenue share. The 3D bioprinters segment is further segmented into inkjet, laser, magnetic, and micro-extrusion/syringe bioprinters. The inkjet 3D bioprinters lead the segment with the largest revenue share. 3D bioprinters assist in building up the materials to construct 3D tissue using the layer-by-layer methodology, while the development of this structure can be assisted by various types of bioprinters. Inkjet printers provide a high resolution and high cell viability. Additionally, inkjet bioprinters come with several advantages, such as outstanding speed, easy availability, and affordability. These factors are expected to support the revenue growth of this segment during the forecast period. However, unreliable cell encapsulation or problems related to the droplet directions are some of the drawbacks of inkjet bioprinters. 

3D Bioprinting Market by Materials

Based on the materials, the global 3D bioprinting market is segmented into hydrogel, cell, extracellular matrices, and biomaterials. 

The hydrogel, or collagen, segment accounts for the largest revenue share of the market. The revenue growth of this segment can be attributed to wide utilization of hydrogel in the development of bone, skin, tendons, and various other soft tissues. Hydrogel assists in forming fibrous networking, and has high biodegradability, and biocompatibility.

3D Bioprinting Market by Application

Based on the application, the global 3D bioprinting market is segmented into pharmaceuticals, organ & tissue regeneration, 3D cell culture, and others. 

The pharmaceuticals segment accounts for the largest revenue share of the global market. The revenue growth of this segment can be attributed to increasing demand for novel drugs due to rise in the prevalence of chronic diseases. Furthermore, growing popularity and adoption of personalized drugs is expected to contribute to the revenue growth of this segment in the next few years. 

3D Bioprinting Market by End User

Based on the end user, the global 3D bioprinting market is segmented into research centers & academics, biopharmaceutical, and others.

The biopharmaceutical segment leads the market with the largest revenue share. The revenue growth of this segment can be attributed to increasing need for effectual drugs and therapies (especially in oncology) and rising usage of tissue modeling and miniature cellular models. 

3D Bioprinting Market by Region

Based on the region, the global 3D bioprinting market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America dominates the market due to its largest revenue share. The revenue growth of this region can be attributed to high prevalence of chronic diseases and increase in the number of transplantation procedures in the region. For instance, around 110,000 individuals in the U.S. are on the waiting list for organ transplant procedures, and about 20 to 25 patients die every day owing to a lack of organ transplantation, according to the Health Resources and Services Administration (HRSA). Additionally, presence of major players in this region further fuels the revenue growth in the North America market. 

3D Bioprinting Market Competitive Landscape

The prominent players operating in the global 3D bioprinting market are:

• Allevi Inc.
• EnvisionTEC Inc.
• Organovo Holdings Inc.
• RegenHU 
• Bico Group AB
• Collplant Biotechnologies Ltd.
• Cyfuse Biomedical K.K.
• Advanced Solutions Life Sciences LLC
• Aspect Biosystems Ltd.
• Vivax Bio LLC
• Regemat 3D S.L.
• Inventia Life Science PTY LTD.

3D Bioprinting Market Strategic Developments

• In June 2022, Brinter, a Finnish bioprinting company, developed the world's first multi-material, multi-fluidic bioprinting printhead. With the launch of this advanced technology, the company focuses on expanding its bioprinter device sales in the U.S. and Europe markets.

Frequently Asked Questions About This Report